172 related articles for article (PubMed ID: 21639815)
1. Early changes in parathyroid hormone concentrations in HIV-infected patients initiating antiretroviral therapy with tenofovir.
Masiá M; Padilla S; Robledano C; López N; Ramos JM; Gutiérrez F
AIDS Res Hum Retroviruses; 2012 Mar; 28(3):242-6. PubMed ID: 21639815
[TBL] [Abstract][Full Text] [Related]
2. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.
Post FA; Moyle GJ; Stellbrink HJ; Domingo P; Podzamczer D; Fisher M; Norden AG; Cavassini M; Rieger A; Khuong-Josses MA; Branco T; Pearce HC; Givens N; Vavro C; Lim ML
J Acquir Immune Defic Syndr; 2010 Sep; 55(1):49-57. PubMed ID: 20431394
[TBL] [Abstract][Full Text] [Related]
3. Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users.
Childs KE; Fishman SL; Constable C; Gutierrez JA; Wyatt CM; Dieterich DT; Mullen MP; Branch AD
AIDS Res Hum Retroviruses; 2010 Aug; 26(8):855-9. PubMed ID: 20672993
[TBL] [Abstract][Full Text] [Related]
4. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
Martínez E; Arranz JA; Podzamczer D; Loncá M; Sanz J; Barragán P; Ribera E; Knobel H; Roca V; Gutiérrez F; Blanco JL; Mallolas J; Llibre JM; Clotet B; Dalmau D; Segura F; Arribas JR; Cosín J; Barrufet P; Casas E; Ferrer E; Curran A; González A; Pich J; Cruceta A; Arnaiz JA; Miró JM; Gatell JM;
J Acquir Immune Defic Syndr; 2009 Jul; 51(3):290-7. PubMed ID: 19398921
[TBL] [Abstract][Full Text] [Related]
5. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Manfredi R; Calza L
AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
Vourvahis M; Davis J; Langdon G; Layton G; Fang J; Choo HW; Hansson AG; Tawadrous M
Antivir Ther; 2013; 18(6):745-54. PubMed ID: 23558061
[TBL] [Abstract][Full Text] [Related]
7. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
Martínez E; Larrousse M; Podzamczer D; Pérez I; Gutiérrez F; Loncá M; Barragán P; Deulofeu R; Casamitjana R; Mallolas J; Pich J; Gatell JM;
AIDS; 2010 Jan; 24(3):F1-9. PubMed ID: 20009917
[TBL] [Abstract][Full Text] [Related]
8. Treatment of calcium and vitamin D deficiency in HIV-positive men on tenofovir-containing antiretroviral therapy.
Bech A; Van Bentum P; Telting D; Gisolf J; Richter C; De Boer H
HIV Clin Trials; 2012; 13(6):350-6. PubMed ID: 23195673
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy.
Rasmussen TA; Tolstrup M; Melchjorsen J; Frederiksen CA; Nielsen US; Langdahl BL; Østergaard L; Laursen AL
BMC Infect Dis; 2011 Oct; 11():267. PubMed ID: 21970555
[TBL] [Abstract][Full Text] [Related]
10. Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
Haskelberg H; Hoy JF; Amin J; Ebeling PR; Emery S; Carr A; STEAL Study Group
PLoS One; 2012; 7(6):e38377. PubMed ID: 22719882
[TBL] [Abstract][Full Text] [Related]
11. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.
Stellbrink HJ; Orkin C; Arribas JR; Compston J; Gerstoft J; Van Wijngaerden E; Lazzarin A; Rizzardini G; Sprenger HG; Lambert J; Sture G; Leather D; Hughes S; Zucchi P; Pearce H;
Clin Infect Dis; 2010 Oct; 51(8):963-72. PubMed ID: 20828304
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of tenofovir/emtricitabine or abacavir/lamivudine in combination with efavirenz in treatment naïve HIV patients: a 5 year retrospective observational cohort study. (the TOKEN Study).
Pammi M; Arumainayagam J; Kumari B; Ahmed-Jushuf I; Carlin EM; Chandramani S; Riddell L; Ghanem M; Das S
Int J Clin Pract; 2013 Sep; 67(9):922-3. PubMed ID: 23952469
[No Abstract] [Full Text] [Related]
13. Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.
Abgrall S; Ingle SM; May MT; Costagliola D; Mercie P; Cavassini M; Reekie J; Samji H; Gill MJ; Crane HM; Tate J; Sterling TR; Antinori A; Reiss P; Saag MS; Mugavero MJ; Phillips A; Manzardo C; Wasmuth JC; Stephan C; Guest JL; Gomez Sirvent JL; Sterne JA;
AIDS; 2013 Mar; 27(5):803-13. PubMed ID: 23719350
[TBL] [Abstract][Full Text] [Related]
14. Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.
Havens PL; Long D; Schuster GU; Gordon CM; Price G; Wilson CM; Kapogiannis BG; Mulligan K; Stephensen CB;
Antivir Ther; 2018; 23(7):623-628. PubMed ID: 30260797
[TBL] [Abstract][Full Text] [Related]
15. The impact of gender and anchor drugs on TDF renal toxicity.
Quiros-Roldan E; Amadasi S; Paraninfo G; Izzo I; Allegri R; Motta D; Gatti F; Cristini G; Carosi G; Mendeni M; Torti C
J Acquir Immune Defic Syndr; 2010 Oct; 55(2):e11-2. PubMed ID: 20859083
[No Abstract] [Full Text] [Related]
16. Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?
Havens PL; Kiser JJ; Stephensen CB; Hazra R; Flynn PM; Wilson CM; Rutledge B; Bethel J; Pan CG; Woodhouse LR; Van Loan MD; Liu N; Lujan-Zilbermann J; Baker A; Kapogiannis BG; Gordon CM; Mulligan K;
Antimicrob Agents Chemother; 2013 Nov; 57(11):5619-28. PubMed ID: 24002093
[TBL] [Abstract][Full Text] [Related]
17. Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir.
Maggi P; Montinaro V; Bellacosa C; Pietanza S; Volpe A; Graziano G; Strippoli GF; Angarano G
AIDS Patient Care STDS; 2012 Jan; 26(1):5-11. PubMed ID: 22136504
[TBL] [Abstract][Full Text] [Related]
18. Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV.
Klassen KM; Kimlin MG; Fairley CK; Emery S; Anderson PH; Ebeling PR;
Osteoporos Int; 2016 May; 27(5):1737-45. PubMed ID: 26659069
[TBL] [Abstract][Full Text] [Related]
19. Neutrophil gelatinase-associated lipocalin, a marker of tubular dysfunction, is not increased in long-term virologically controlled patients receiving a tenofovir/emtricitabine + nevirapine regimen.
Allavena C; Bach-Ngohou K; Billaud E; Sécher S; Dejoie T; Reliquet V; Fakhouri F; Raffi F
J Antimicrob Chemother; 2013 Dec; 68(12):2866-70. PubMed ID: 23818285
[TBL] [Abstract][Full Text] [Related]
20. Safety, efficacy, and persistence of emtricitabine/tenofovir versus other nucleoside analogues in naive subjects aged 50 years or older in Spain: the TRIP study.
Blanco JR; Caro-Murillo AM; Castaño MA; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Riera M; Pulido F; Vera F; Romero-Palacios A; Aguirrebengoa K; Portilla J; Ferrer P; Pedrol E
HIV Clin Trials; 2013; 14(5):204-15. PubMed ID: 24144897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
